Replies to post #209073 on Biotech Values

[DewDiligence]

HOLX touts proprietary diagnostic for deciding whether to administer extended (2.5-5yr) endocrine therapy in ER+ HER2- breast cancer:

https://www.businesswire.com/news/home/20211210005080/en

HOLX is the leading manufacturer of 3D mammogram devices.